Ruffer LLP Invests $3.22 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Key Points

• Ruffer LLP has acquired a new position in Halozyme Therapeutics, purchasing 50,414 shares valued at approximately $3.2 million in the first quarter.
• Insider transactions include CEO Helen Torley's sale of 20,000 shares for $1.13 million, reducing her ownership stake by 2.65%.
• Analyst ratings for Halozyme Therapeutics show mixed sentiment, with two sell ratings, six hold ratings, and four buy ratings, reflecting a consensus rating of "Hold" with an average price target of $62.70.

Ruffer LLP acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 50,414 shares of the biopharmaceutical company's stock, valued at approximately $3,217,000.

Several other hedge funds have also recently modified their holdings of the business. Snyder Capital Management L P boosted its stake in Halozyme Therapeutics by 2.6% during the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock worth $199,294,000 after purchasing an additional 105,086 shares during the last quarter. Congress Asset Management Co. increased its position in shares of Halozyme Therapeutics by 8.8% during the first quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company's stock worth $136,088,000 after purchasing an additional 172,971 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Halozyme Therapeutics by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock valued at $92,446,000 after acquiring an additional 47,795 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock valued at $87,386,000 after buying an additional 145,617 shares during the period. Finally, TD Asset Management Inc boosted its position in shares of Halozyme Therapeutics by 5.8% in the 1st quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company's stock worth $92,642,000 after buying an additional 79,708 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO traded up $1.52 during trading hours on Wednesday, hitting $62.33. The company's stock had a trading volume of 5,658,608 shares, compared to its average volume of 1,381,058. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. The company has a market capitalization of $7.68 billion, a P/E ratio of 14.26, a PEG ratio of 0.41 and a beta of 1.17. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.50. The stock has a fifty day simple moving average of $55.53 and a 200-day simple moving average of $57.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. The business had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 142.12% and a net margin of 47.28%. The firm's revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.91 earnings per share. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HALO. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. The Goldman Sachs Group assumed coverage on Halozyme Therapeutics in a research report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective for the company. Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective for the company. in a research note on Tuesday, May 13th. Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $58.00 to $60.00 and gave the company a "neutral" rating in a research note on Wednesday, July 16th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $66.10.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at $41,403,763.17. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 60,000 shares of company stock worth $3,262,400 in the last three months. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.